Liposomal Bupivacaine in Benign Soft Tissue Tumor Resection

Status unconfirmed · Phase 4

Conditions studied: Benign Neoplasm

In brief

Liposomal bupivacaine (Exparel) has been used as an adjunct to pain management in the perioperative setting. However, the efficacy of the drug has not bewen studied in patients with benign soft tissue tumor resections. The goal of the study is to see if Exparel controls pain and improves functional outcomes for patients after these procedures compared to the current standard Bupivacaine HCL.

Key facts

Study ID

NCT05082441

Run by

Samaritan Health Services

People needed

140

Starts

2020-09-01

Expected to finish

2022-09-01

Last updated by the study team

2021-10-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• All benign soft tissue tumors greater than one cubic cm
• Adults 18 years and older

You may not qualify if…

• Pregnant females
• Women who are breastfeeding
• Less than 18 years old
• Malignant tumors
• Tumors smaller than 1 cubic cm
• Allergy to Exparel
• Patients who are opioid dependent defined as patients on a long acting narcotic or who take more than 30 morphine equivalents per day
• Allergy to amide anesthetics
• bone tumors
• Patients unable to comply with the study standards and follow up

Where it is running

• Good Samaritan Regional Medical Center — Corvallis, Oregon, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.